STAT3 can be continuously activated by non-receptor tyrosine kinases, such as Janus kinase (JAK), which constitutes the JAK/STAT3 pathway and participates in the progression of RCC (Zhong et al., 2016; Xu et al., 2022). This evidence concerns the gene STAT3 and renal cell adenocarcinoma.